Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients


High-dose interferon alfa-2b (IFNα-2b) is the only approved adjuvant systemic therapy for resected, high risk melanoma in the United States (Fecher and Flaherty, in Natl Compr Cancer Netw 7:295–304, 2009). Recently, two important meta-analyses of randomized trials (Wheatley et al., in J Clin Oncol, 2007; Mocellin et al. in J Natl Cancer Inst, 2010… (More)
DOI: 10.1007/s10585-012-9504-2


5 Figures and Tables